Immune to Cancer: The CRI Blog
-
Nivolumab Approved for Patients with Chemotherapy-Resistant, Metastatic, MSI-H Colorectal Cancer
Nivolumab becomes second checkpoint immunotherapy approved for colorectal cancer
-
Immunotherapy Makes History with Latest Cancer Approval
The FDA’s biomarker-based approval of Keytruda was the first of its kind
-
FDA approves Keytruda combo for first-line lung cancer treatment
Patients in the U.S. who have advanced nonsquamous non-small cell lung cancer can now receive Keytruda as…
-
Durvalumab Becomes Newest Immunotherapy Approved for Advanced Bladder Cancer
Durvalumab marks AstraZeneca’s first immunotherapy approval
-
Pembrolizumab Approved for Children and Adults with Hard-to-Treat Hodgkin Lymphoma
Pembrolizumab is second anti-PD-1 drug approved for adults with cHL, first for any childhood cancer
-
Pembrolizumab (Keytruda®) Approved as First-Line Option for Lung Cancer
Anti-PD-1 checkpoint antibody is the only immunotherapy approved for first-line treatment for lung cancer patients.
-
FDA Approves Another Immunotherapy Option for Patients with Advanced Lung Cancer
Anti-PD-L1 atezolizumab is the second PD-1 pathway drug approved for lung cancer this month.
-
FDA Approves Pembrolizumab (Keytruda®), a PD-1 Antibody, for Head and Neck Cancer
New hope now exists for patients with advanced head and neck cancer.
-
Atezolizumab (Tecentriq™) Receives FDA Approval for Bladder Cancer
It becomes the first FDA-approved checkpoint blockade immunotherapy for bladder cancer.